北京北陆药业股份有限公司（以下简称"公司"）已于2023年4月24日在 巨潮资讯网（www.cninfo.com.cn）披露《2022年年度报告》。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年 5月10日（星期三）下午15:00至17:00时在"北陆药业投资者关系"小程序举行 2022年度网上业绩说明会。本次网上业绩说明会将采用网络远程的方式举行， 投资者可登陆"北陆药业投资者关系"小程序参与互动交流。为广泛听取投资 者的意见和建议，提前向投资者征集问题，提问通道自发出公告之日起开放。 参与方式一：在微信小程序中搜索"北陆药业投资者关系"； 参与方式二：微信扫一扫以下二维码： 投资者依据提示，授权登入"北陆药业投资者关系"小程序，即可参与 股票代码：300016 股票简称：北陆药业 公告编号：2023-036 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于召开2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 敬请广大投资者积极参与。 特此公告。 北京北陆药业股份有限公司 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 188.04 million, representing a year-over-year increase of 2.23% compared to CNY 183.93 million in the same period last year[4]. - Net profit attributable to shareholders decreased by 67.97% to CNY 12.58 million from CNY 39.26 million in the previous year[4]. - The net profit after deducting non-recurring gains and losses fell by 74.38% to CNY 8.61 million from CNY 33.60 million year-over-year[4]. - Total operating revenue for Q1 2023 was CNY 188,036,687.69, an increase of 2.4% compared to CNY 183,930,040.70 in Q1 2022[30]. - Net profit for Q1 2023 was CNY 10,184,088.91, a decrease of 70.7% from CNY 34,776,332.03 in Q1 2022[31]. - The company reported a gross profit margin of approximately 5.4% for Q1 2023, down from 19.5% in Q1 2022[30]. - The company's basic earnings per share for Q1 2023 was CNY 0.0256, down from CNY 0.0800 in Q1 2022[31]. Research and Development - The company reported a significant increase in R&D expenses, totaling CNY 17.04 million, which is a 128.07% increase compared to the previous year[10]. - R&D investment reached 17.04 million yuan in Q1 2023, a year-on-year increase of 128.07%[18]. - The company continues to develop products in the fields of contrast agents, endocrinology, cardiovascular, and digestive systems[18]. Cash Flow and Liquidity - Operating cash flow for the period was CNY 35.85 million, reflecting a 67.68% increase from CNY 21.38 million in the same quarter last year[10]. - The company’s cash flow from operating activities showed a significant decline, impacting liquidity[33]. - The net cash flow from operating activities increased to ¥35,846,735.41 from ¥21,378,261.26, representing a growth of approximately 67.9%[34]. - Cash inflow from operating activities totaled ¥225,116,862.35, slightly down from ¥228,618,017.48, a decrease of about 1.1%[34]. - Cash outflow from operating activities decreased to ¥189,270,126.94 from ¥207,239,756.22, a reduction of approximately 8.7%[34]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2.88 billion, up 2.21% from CNY 2.82 billion at the end of the previous year[6]. - Total assets amounted to CNY 2,877,714,818.93, an increase from CNY 2,815,514,459.14 year-over-year[27]. - Total liabilities increased to CNY 943,745,424.99, compared to CNY 892,274,093.48 in the previous year[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 28,755[13]. - The largest shareholder, Wang Daixue, holds 20.87% of shares, amounting to 102,664,727 shares, with 18,643,520 shares pledged[13]. Market Strategy - The company is actively expanding its market outside of centralized procurement, with ongoing efforts in provincial procurement[16]. - The company plans to focus on market expansion and new product development in the upcoming quarters to drive growth[26]. Cash Management - The company's cash and cash equivalents decreased by 14.12% to CNY 65.85 million compared to the beginning of the period[9]. - The company’s cash and cash equivalents at the end of Q1 2023 were 658,452,394.74 yuan, down from 766,734,641.15 yuan at the beginning of the year[23]. - The ending balance of cash and cash equivalents was ¥628,227,882.71, compared to ¥407,009,554.60 in the previous period, an increase of about 54.2%[36]. - The company received cash from borrowings amounting to ¥69,800,000.00, an increase from ¥57,276,000.00, representing a growth of approximately 22.1%[36]. - The company reported a cash inflow of ¥230,000,000.00 from other investment activities, a substantial increase from ¥10,000,000.00, marking a growth of approximately 2200%[34].

Financial Performance - The company achieved operating revenue of 766 million RMB in 2022, a year-on-year decrease of 10.93%[5] - Operating costs increased by 5.31% year-on-year, resulting in a gross profit margin of 55.39%, down 6.88 percentage points from the previous year[5] - Net profit attributable to shareholders was 11.21 million RMB, a significant decrease of 91.07% year-on-year; the net profit after deducting non-recurring gains and losses was -26.63 million RMB, down 128.31%[5] - The company's operating revenue for 2022 was ¥765,881,882.25, a decrease of 10.93% compared to ¥843,901,446.44 in 2021[20] - The net profit attributable to shareholders was ¥11,206,263.74, reflecting a significant decline of 91.07% from ¥124,990,316.67 in the previous year[20] - The basic earnings per share dropped by 92.31% to ¥0.02 from ¥0.25 in the previous year[20] - The diluted earnings per share also fell by 71.43% to ¥0.08 compared to ¥0.28 in 2021[20] - The company reported a total of ¥37,834,555.36 in non-recurring gains and losses for 2022, an increase from ¥31,469,557.01 in 2021[30] - The company experienced a negative net profit of ¥26,628,291.62 after deducting non-recurring gains and losses, a decline of 128.31% from ¥93,520,759.66 in 2021[20] - The company’s weighted average return on net assets decreased to 0.61% from 7.00% in the previous year[20] Research and Development - R&D investment increased by 48.17 million RMB, a year-on-year growth of 93.37%, focusing on product pipelines in contrast agents, cardiovascular, digestive, and endocrine systems[5] - R&D investment amounted to ¥99,764,743.40 in 2022, representing 13.03% of total revenue, up from 6.00% in 2021[84] - The number of R&D personnel rose by 31.06% to 173 in 2022, with a notable increase in higher degree holders, including a 100% increase in master's degree holders[82] - Nearly 40 projects are in the R&D pipeline, with multiple products expected to be approved for market launch in the next two to three years[54] - The company is focusing on product innovation in traditional Chinese medicine, with ongoing development of health products related to Jiuwei Zhenxin Granules expected to be approved next year[39] - The company has multiple ongoing research projects, including 24 products in various stages of development, with several under CDE review, such as the new class 4 drug for Parkinson's disease, Pramipexole Hydrochloride Sustained-Release Tablets[43] Market Strategy and Operations - The company plans to strengthen R&D investment and integrate marketing resources to enhance efficiency and improve performance[6] - The company is adjusting its strategy based on external market conditions to ensure stable development[6] - The marketing strategy has been restructured to improve efficiency, shifting from product line-based teams to channel-based teams, enhancing resource integration and team motivation[48] - The company is actively expanding its overseas market presence, with 23 countries or regions signed for contrast agent products and ongoing registration for Jiuwei Zhenxin Granules in Hong Kong and Thailand[42] - The company has initiated the construction of the Cangzhou Phase III raw material production project, which will strengthen its competitive position in gadolinium and iodine contrast agent raw materials[41] - The company is facing significant pressure from the sharp increase in iodine prices, which has impacted its operations[114] - The company is promoting its original product, Jiuwei Zhenxin Granules, which is recognized as the first pure traditional Chinese medicine approved for treating generalized anxiety disorder, and is expanding its influence in the market[49] Financial Management and Investments - The company has increased its stake in Haichang Pharmaceutical to 51.05% by investing 123 million yuan, achieving absolute control over the subsidiary[53] - The company reported a net increase in cash and cash equivalents of -¥123,395,276.35 in 2022, a slight improvement from -¥135,452,543.98 in 2021[85] - The total amount of financial liabilities decreased by ¥2,451,146.56 during the reporting period[92] - The company has not engaged in any securities or derivative investments during the reporting period[97][98] - The company has established a comprehensive management system covering sales policies, procurement, production, quality management, and financial management to ensure orderly operations[172] Governance and Management - The company has a governance structure that includes independent directors and a supervisory board[134] - The company’s management team includes a mix of experienced professionals, with ages ranging from 31 to 62 years[136] - The company has implemented a share repurchase program, as indicated by the changes in shareholdings among executives[136] - The company is focused on maintaining a diverse and experienced board to guide its strategic direction[134] - The company has a clear strategy for market expansion and product development, as indicated by the appointments and roles of its senior management team[140] Environmental and Social Responsibility - The company has established a comprehensive environmental monitoring scheme to ensure compliance with regulations[189] - The company has received various environmental approvals and has completed necessary environmental impact assessments for its projects[182] - The company has committed to distributing at least 10% of the annual distributable profits as cash dividends for the years 2020 to 2022[195] - The company has provided a total of 2 million yuan in aid to Dazhangzi Village, benefiting low-income households and improving their living conditions[192] - The company has not faced any administrative penalties due to environmental issues during the reporting period[190] Shareholder Engagement - A cash dividend of 0.70 RMB per 10 shares (including tax) was proposed for shareholders, with no bonus shares issued[7] - The company distributed cash dividends of 0.70 RMB per 10 shares, totaling 34,490,317.33 RMB, based on a total share capital of 492,718,819 shares[161] - The company held five temporary shareholder meetings in 2022, with participation rates ranging from 22.22% to 22.42%[133] - The annual shareholder meeting for 2021 had a participation rate of 31.41%[133] - The cash dividend distribution plan is subject to approval at the 2022 annual general meeting[165]

Financial Performance - The company's revenue for Q3 2022 was CNY 206,045,270.60, representing a 41.55% increase year-over-year[4] - The net profit attributable to shareholders for the same period was CNY 15,231,115.85, up 14.82% year-over-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased significantly by 339.18% to CNY 5,798,432.20[4] - The company’s diluted earnings per share for Q3 2022 was CNY 0.0468, a decrease of 47.82% year-over-year[4] - The net profit attributable to the parent company's shareholders for the current period is ¥55,234,553.29, a decrease of 57.5% compared to ¥129,741,225.13 in the previous period[38] - The total comprehensive income attributable to the parent company's owners is ¥55,234,553.29, a decline of 57.4% from ¥129,677,202.02 in the previous period[38] - The basic earnings per share for the current period is ¥0.1126, compared to ¥0.2653 in the previous period, reflecting a decrease of 57.6%[38] - Net profit for the quarter was CNY 42,188,946.08, a decline of 65.4% compared to CNY 122,069,471.17 in the same period last year[36] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,815,909,512.83, a decrease of 3.00% compared to the end of the previous year[6] - Total liabilities increased to CNY 845,103,099.77, up from CNY 818,223,668.61, representing a rise of 3.3%[33] - Cash and cash equivalents were reported at CNY 382,809,017.74, down from CNY 895,023,071.26, indicating a decrease of 57.3%[31] - Inventory levels rose to CNY 288,476,715.03, an increase of 15.4% compared to CNY 250,009,438.55 in the previous year[31] - The company reported a significant increase in long-term equity investments, totaling CNY 215,876,136.56, slightly down from CNY 217,851,563.09[31] Cash Flow - The company has initiated several new R&D projects, which are progressing according to schedule, contributing to increased R&D expenditures[10] - The company's cash flow from operating activities for the year-to-date was CNY 94,876,544.89, down 37.64% year-over-year[4] - The net cash flow from operating activities for the current period is ¥94,876,544.89, down 37.5% from ¥152,132,123.63 in the previous period[40] - The total cash inflow from operating activities is ¥711,657,213.65, down 9.8% from ¥789,062,437.39 in the previous period[40] - The total cash outflow from operating activities is ¥616,780,668.76, a decrease of 3.2% compared to ¥636,930,313.76 in the previous period[40] - The net cash flow from investing activities is -¥459,857,303.61, an improvement from -¥511,659,837.06 in the previous period[42] - The cash flow from financing activities shows a net outflow of -¥142,969,483.83, compared to -¥111,176,875.83 in the previous period[42] Research and Development - Research and development expenses for the year-to-date reached CNY 64,582,400.00, an increase of 100.45% year-over-year, indicating a significant investment in new projects[11] - Research and development investment reached 65.27 million RMB in the first three quarters, an increase of 83.18% year-on-year[22] - The company has established a full-scale research subsidiary to support its high-end generic and innovative drug development[23] - The company has nearly 40 projects in development across various therapeutic areas, with multiple products expected to be approved for market in the next two to three years[23] - Research and development expenses increased significantly to CNY 64,582,430.73, up 100.1% from CNY 32,218,332.46 year-over-year[36] Market Strategy and Operations - The company is expanding its overseas market presence, particularly in the South American region, and is progressing with EU EDQM GMP certification for its contrast agents[24] - The company acquired 9.1 million shares of Haichang Pharmaceutical, increasing its direct ownership to 51.05% and total ownership with concerted actions to 79.75%[26] - The company is restructuring its organizational framework and management processes to enhance operational efficiency and profitability[25] - The company plans to focus on quality improvement, cost reduction, and accelerating research and development as key strategies for the upcoming year[25] - The marketing efforts across all product lines have shown significant progress, leading to improved performance compared to the previous quarter[21] - The company plans to focus on market expansion and new product development as part of its future strategy[32] Operating Performance - Total operating revenue for the third quarter was CNY 557,308,788.59, a decrease of 18.1% compared to CNY 680,836,560.47 in the previous year[36] - Total operating costs amounted to CNY 543,700,002.57, down 4.2% from CNY 567,782,115.32 year-over-year[36] - The company reported a decrease in net profit margin due to the impact of centralized procurement and price reductions on core products[10]

Product Development and Market Expansion - Beijing Beilu Pharmaceutical has expanded its product offerings to include 22 specifications of contrast agents, covering gadolinium and iodine series[4] - The company serves over 5,500 hospitals domestically and has begun international expansion, with products sold in 23 countries[6] - Future strategies include deepening focus on the contrast agent sector, increasing R&D investment, and optimizing production processes to reduce costs[6] - The company aims to maintain a commitment to internationalization while enhancing its local market presence[6] - The company has developed and reserved multiple central nervous system products, aiming to enhance the influence of its "Jiuwei" brand series[37] - The company is actively pursuing international expansion, having signed agreements with clients in 23 countries or regions[61] - The company is advancing multiple investment projects, including a high-end intelligent injection workshop and a new raw material production line in Cangzhou[57] Financial Performance - The company's operating revenue for the reporting period was ¥351.26 million, a decrease of 34.38% compared to the same period last year[23] - Net profit attributable to shareholders was ¥40.00 million, down 65.66% year-on-year[23] - The net profit after deducting non-recurring gains and losses was ¥16.51 million, a decline of 84.67% compared to the previous year[23] - Sales revenue from contrast agents reached ¥250.75 million, a decrease of 38.02% year-on-year, with the iodine contrast agent sales dropping by 55.94%[36] - The sales revenue of the strategic product "Jiuwei Zhenxin Granules" was ¥59.63 million, down 26.49% year-on-year[37] - Operating cash flow decreased by 45.21% to CNY 56.20 million, primarily due to increased payments for raw material procurement[66] - The company achieved operating revenue of CNY 351.26 million, a decrease of 34.38% year-on-year, primarily due to significant price declines in multiple products following national centralized procurement results[50][64] Research and Development - The company has multiple ongoing R&D projects, including 28 products in various stages, with key approvals for iodipamide injection and gadobutrol injection[41] - The company is establishing a research institute to enhance its R&D capabilities and target high-demand therapeutic areas such as cardiovascular, digestive, and neurological systems[46] - Research and development expenses increased by 52.30% to CNY 40.50 million, reflecting the company's commitment to advancing its R&D projects[66] - The company has initiated a series of new projects for drug development, with a focus on enhancing its R&D capabilities and expanding its product line through various means[100] Shareholder and Stock Management - No cash dividends or stock bonuses will be distributed to shareholders for this period[9] - The chairman expressed gratitude to shareholders for their continued support over the past 30 years[4] - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period, nor to increase share capital from capital reserves[109] - The company repurchased and canceled a total of 763,180 restricted stocks, adjusting the total number of incentive plan participants to 28 and the number of unvested restricted stocks to 1,240,820[111] - The company’s diluted earnings per share were ¥0.11, a decrease of 56.00% compared to the same period last year[23] Environmental and Social Responsibility - Beijing Beilu Pharmaceutical Co., Ltd. has established waste gas treatment facilities including condensation and water spraying for its extraction workshop, and alkaline spraying combined with low-temperature plasma for its wastewater station[117] - Zhejiang Haichang Pharmaceutical Co., Ltd. has completed and is operating environmental protection facilities for wastewater, waste gas, noise, and hazardous solid waste[117] - The company has provided a total of 2 million yuan in aid to support impoverished households in Dazhangzi Village since 2018, with 200,000 yuan distributed in the reporting period[125] - The company has established emergency response plans for environmental incidents, with regular drills conducted[122] Corporate Governance and Compliance - The company has not engaged in any major litigation or arbitration matters during the reporting period[134] - There were no significant related party transactions or non-operating fund occupation by controlling shareholders during the reporting period[139] - The company has ensured timely, truthful, accurate, and complete disclosure of the use of raised funds, with no violations in storage, usage, management, and disclosure[87] Investment and Asset Management - The total assets at the end of the reporting period were ¥2.96 billion, an increase of 2.06% from the end of the previous year[23] - The company has committed a total investment of CNY 50,000 million, with actual cumulative investment reaching CNY 48,922.45 million, representing a progress of 97.85%[85] - The company has increased its stake in Haichang Pharmaceutical to 51.05%, strengthening its control over the contrast agent supply chain[58] - The company has invested in various bank wealth management products, with a total investment amount of ¥23,000.00 million and a reported gain of ¥69.28 million from one of the products[152]

Financial Performance - The company's operating revenue for Q1 2022 was ¥183,930,040.70, a decrease of 17.18% compared to ¥222,075,960.67 in the same period last year[4] - The net profit attributable to shareholders for Q1 2022 was ¥39,263,324.48, down 22.18% from ¥50,451,938.09 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥33,601,161.26, reflecting a decline of 26.73% compared to ¥45,856,829.98 in the previous year[4] - Total revenue for the current period was CNY 183,930,040.70, a decrease of 17.1% compared to CNY 222,075,960.67 in the previous period[28] - Operating profit for the current period was CNY 40,011,884.74, a decline of 24.1% from CNY 52,626,205.95[28] - Net profit for the current period was CNY 34,776,332.03, down 23.2% from CNY 45,325,558.55 in the previous period[30] - Earnings per share decreased to CNY 0.0800 from CNY 0.1032, reflecting a decline of 22.4%[30] Cash Flow - The net cash flow from operating activities was ¥21,378,261.26, a significant drop of 54.71% from ¥47,200,999.98 in the same quarter last year[4] - Total cash inflow from operating activities was ¥228,618,017.48, while cash outflow was ¥207,239,756.22, resulting in a net cash inflow[32] - Cash flow from investing activities showed a net outflow of ¥530,210,081.18, worsening from a net outflow of ¥424,149,576.66 in the previous period[34] - Cash inflow from financing activities was ¥57,276,000.00, with a net cash flow of ¥55,518,667.59 after accounting for cash outflows[34] - The ending balance of cash and cash equivalents decreased to ¥407,009,554.60 from ¥615,431,981.12, reflecting a decline of 33.8%[34] - The company received ¥11,514,250.11 in other operating cash, significantly up from ¥3,778,962.97 in the previous period, indicating a 204.5% increase[32] - Payments for goods and services amounted to ¥107,579,401.07, which is a 37.8% increase from ¥78,120,254.56 in the previous period[32] - The company’s cash flow from financing activities included dividend payments of ¥1,757,332.41, down from ¥3,438,433.51 in the previous period[34] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥2,967,839,366.78, an increase of 2.24% from ¥2,902,882,759.22 at the end of the previous year[4] - Total assets increased to CNY 2,967,839,366.78 from CNY 2,902,882,759.22, representing a growth of 2.2%[25] - Total liabilities rose to CNY 847,710,716.82, an increase of 3.6% from CNY 818,223,668.61[25] - Non-current assets totaled CNY 1,593,629,157.99, slightly down from CNY 1,596,804,307.53, a decrease of 0.2%[25] - The company experienced a 51.20% decrease in cash and cash equivalents at the end of the period, totaling ¥43,677,650.00[10] - The company’s accounts receivable decreased from 133,730,179.27 CNY to 110,453,164.68 CNY[21] - The inventory increased slightly from 250,009,438.55 CNY to 252,959,098.35 CNY[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 32,353[14] - The largest shareholder, Wang Daixue, holds 21.83% of shares, totaling 107,537,613 shares, with 80,653,210 shares pledged[14] - The total number of restricted shares at the end of the period is 83,554,460, down from 85,958,375 at the beginning of the period[18] Research and Development - Research and development expenses for the period were ¥747,230.00, a decrease of 47.36% year-on-year, attributed to reduced investment in R&D projects[10] - The company has completed the consistency evaluation of the quality and efficacy of Iopamidol injection[19] - The company has obtained the drug registration certificate for Gadobutrol injection[19] - The company has changed the use of raised funds from the "Cangzhou solid preparation new workshop project" to the "Cangzhou Phase III raw material drug production project"[19] Future Outlook - The company plans to focus on market expansion and new product development in the upcoming quarters[24]

Financial Performance - The company's operating revenue for 2021 was approximately ¥843.90 million, representing a 2.00% increase compared to ¥827.34 million in 2020[19]. - The net profit attributable to shareholders decreased by 28.46% to approximately ¥124.99 million from ¥174.70 million in 2020[19]. - The net profit after deducting non-recurring gains and losses was approximately ¥93.52 million, down 38.36% from ¥151.73 million in 2020[19]. - The net cash flow from operating activities was approximately ¥108.73 million, a decrease of 38.22% compared to ¥176.00 million in 2020[19]. - Basic earnings per share fell by 30.56% to ¥0.25 from ¥0.36 in 2020[19]. - The total assets at the end of 2021 were approximately ¥2.90 billion, an increase of 1.94% from ¥2.85 billion at the end of 2020[19]. - The net assets attributable to shareholders increased by 6.58% to approximately ¥1.86 billion from ¥1.74 billion at the end of 2020[19]. - The weighted average return on net assets decreased to 7.00% from 11.49% in 2020, a decline of 4.49 percentage points[19]. Revenue Breakdown - In Q1 2021, the company reported revenue of approximately ¥222.08 million, with a net profit attributable to shareholders of about ¥50.45 million[21]. - The company's revenue in Q2 2021 increased to approximately ¥313.20 million, with net profit rising to about ¥66.02 million[21]. - In Q3 2021, revenue dropped to approximately ¥145.56 million, and net profit fell to ¥13.26 million, indicating a significant decline[21]. - The company’s contrast agent products generated sales revenue of approximately ¥635.69 million in 2021, remaining stable compared to the previous year[32]. - The iodine contrast agent injection product achieved sales revenue of approximately ¥32.99 million in Q4 2021, reflecting a year-on-year increase of 19.69%[32]. - The sales revenue of Jiwei Zhenxin Granules reached 141.40 million yuan, an increase of 26.96% year-on-year[38]. - The sales revenue of the company's hypoglycemic products, including Glimepiride and Repaglinide, declined to 48.88 million yuan, a decrease of 31.11% year-on-year[39]. - Haichang Pharmaceutical achieved a sales revenue of 124.44 million yuan, a significant increase of 1798.27% year-on-year, marking a historical high for the company[41]. Investment and Expansion Plans - The company plans to invest 192 million yuan to enhance its production capabilities in gadolinium and iodine contrast agents, aiming to improve cost and competitive advantages[43]. - The company plans to diversify its contrast agent product line with the anticipated launch of gadobutrol injection within the year[34]. - The company is actively expanding its overseas market, achieving sales of contrast agents in 6 countries, with 5 countries completing registration[58]. - The company plans to deepen its focus on the contrast agent and raw material drug sectors, aiming to enhance domestic market share and sales growth[112]. - The company intends to increase R&D investment, targeting at least three new product projects each year through various development strategies[112]. - The company aims to accelerate overseas registration and market expansion to boost international sales[113]. - The company will actively pursue international market expansion for its contrast agents and raw materials, with a focus on obtaining EU compliance certification for its production facilities[125]. Research and Development - The company is focusing on the development of multiple central nervous system products, which are expected to synergize with Jiwei Zhenxin Granules to enhance brand influence[45]. - The number of R&D personnel increased by 23.36% to 132 in 2021, with a higher proportion of personnel holding bachelor's degrees[82]. - R&D investment amounted to ¥51,593,248.72 in 2021, accounting for 6.11% of operating revenue, down from 7.25% in 2020[82]. - The company will establish a comprehensive risk management and control system for its R&D projects to address potential risks in drug development[116]. Corporate Governance - The company maintained compliance with corporate governance standards, aligning with the requirements of the Shenzhen Stock Exchange and relevant laws[132]. - The company has established a complete independent operational capability, ensuring independence from its controlling shareholders in various aspects[132]. - The company’s board of directors and supervisory board operate independently, fulfilling their respective roles[132]. - The company has a diverse board composition, including independent directors with expertise in academia and industry, which supports robust decision-making processes[143][144]. - The company has implemented a stock buyback program, which has resulted in a significant reduction in outstanding shares, thereby potentially increasing shareholder value[139]. Employee and Management - The total number of employees at the end of the reporting period was 905, with 331 in production, 267 in sales, and 185 in technical roles[161]. - The company has established a scientific and reasonable salary management system to improve performance and organizational efficiency[162]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 6.1364 million[149]. - The company has a performance management system in place for determining the remuneration of senior management[147]. Risk Management - The company has outlined various risks and countermeasures in its report, emphasizing the importance of investor awareness regarding potential risks[5]. - The company will enhance its internal control management to effectively control operational risks as a key focus for 2022[129]. - The internal control system was enhanced to address operational, financial, and legal risks, ensuring effective management and compliance with regulations[175]. Social Responsibility - A total of 2 million yuan was allocated for poverty alleviation efforts in the Miyun District, with 400,000 yuan distributed in the reporting period[185]. - The company committed to distributing at least 10% of the distributable profits in cash annually from 2020 to 2022, with compliance confirmed[188].

Financial Performance - The company's revenue for Q3 2021 was CNY 145,560,939.49, a decrease of 43.13% year-on-year[3]. - The net profit attributable to shareholders for Q3 2021 was CNY 13,264,783.86, down 80.76% compared to the same period last year[3]. - The net profit after deducting non-recurring gains and losses was CNY 1,320,272.02, a decline of 97.97% year-on-year[3]. - Total operating revenue for the current period reached ¥680,836,560.47, an increase of 9.1% compared to ¥623,551,564.18 in the previous period[29]. - The company's net profit attributable to shareholders increased to ¥916,228,595.04 from ¥815,934,348.47, a growth of 12.3%[28]. - The net profit for the current period is 122,069,471.17, a decrease of 19.2% compared to 150,800,273.56 in the previous period[30]. - The total profit for the current period is 137,069,838.77, down from 170,924,584.11 in the previous period[30]. - The operating profit for the current period is 141,140,413.13, a decrease from 174,565,382.40 in the previous period[30]. - The total comprehensive income attributable to the parent company owners is 129,677,202.02, down from 160,456,123.17 in the previous period[30]. Cash Flow and Assets - The operating cash flow for the year-to-date period increased by 35.09% to CNY 152,132,123.63[5]. - The cash flow from operating activities net amount is 152,132,123.63, an increase of 35.1% compared to 112,619,157.09 in the previous period[33]. - The cash flow from investing activities shows a net outflow of -511,659,837.06, worsening from -91,671,402.73 in the previous period[35]. - The cash flow from financing activities resulted in a net outflow of -111,176,875.83, compared to a net inflow of 120,396,145.25 in the previous period[35]. - The cash and cash equivalents at the end of the period were CNY 55,438,470.00, a decrease of 45.31% from the beginning of the period[10]. - The company's cash and cash equivalents decreased to ¥554,384,715.16 from ¥1,013,727,678.06, a decline of 45.6%[25]. - The cash and cash equivalents at the end of the period amount to 525,183,317.32, compared to 389,553,993.86 at the end of the previous period[35]. - The total assets at the end of the reporting period were CNY 2,906,673,470.06, an increase of 2.08% from the end of the previous year[5]. - Total assets rose to ¥2,906,673,470.06, compared to ¥2,847,573,506.75, an increase of 2.1%[28]. Liabilities and Shareholder Information - The total liabilities decreased to ¥916,285,173.38 from ¥955,500,130.72, a decline of 4.1%[27]. - The total number of common shareholders at the end of the reporting period is 31,562[15]. - The largest shareholder, Wang Daixue, holds 21.82% of the shares, totaling 107,537,613 shares, with 30,546,030 shares pledged[15]. - The top ten shareholders hold a significant portion of the shares, with the first three shareholders collectively owning over 33%[15]. - The company has a total of 86,098,375 shares under lock-up agreements, primarily due to executive stock options[19]. - The company plans to issue up to 9.1 million shares, expecting to raise no more than 109.2 million yuan for repaying bank loans[22]. Operational Insights - The company reported a significant decrease in sales of its diabetes product and contrast agent due to national procurement policies, impacting revenue[9]. - Inventory at the end of the period increased by 74.18% to CNY 20,399,630.00, attributed to raw material and product stockpiling[10]. - Inventory increased significantly to ¥203,996,299.45 from ¥117,118,440.22, representing a growth of 74.0%[25]. - Research and development expenses were ¥32,218,332.46, slightly down from ¥33,398,300.06 year-over-year[29]. - The company plans to expand its production capacity with ongoing investments in new projects, including a production line for iodine contrast agents[11]. Financial Instruments and Corporate Governance - As of September 30, 2021, the remaining convertible bonds amount to 4,993,363 with a total face value of 499,336,300 yuan[21]. - The company’s subsidiary, Haichang Pharmaceutical, completed the third board and supervisory board re-election on October 13, 2021[22]. - The company’s stock options for executives are subject to a 25% annual transfer limit during their tenure and six months after[18]. - The company’s subsidiary, Haichang Pharmaceutical, passed the consistency evaluation for the quality and efficacy of Gadopentetic Acid Injection in July 2021[20]. - The company’s stock issuance has been approved by the shareholders' meeting and is awaiting further regulatory approvals[22].

Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥535.28 million, representing a 45.61% increase compared to ¥367.62 million in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2021 was approximately ¥116.48 million, an increase of 27.21% from ¥91.56 million in the previous year[21]. - The net profit after deducting non-recurring gains and losses was approximately ¥107.71 million, reflecting a 38.39% increase from ¥77.83 million in the same period last year[21]. - The net cash flow from operating activities was approximately ¥102.58 million, up 58.29% from ¥64.80 million in the previous year[21]. - The basic earnings per share for the first half of 2021 was ¥0.24, an increase of 26.32% compared to ¥0.19 in the same period last year[21]. - The diluted earnings per share for the first half of 2021 was ¥0.25, reflecting a 31.58% increase from ¥0.19 in the previous year[21]. - The weighted average return on equity for the first half of 2021 was 6.47%, up from 6.12% in the same period last year[21]. - The company achieved a revenue of CNY 535.28 million, representing a year-on-year growth of 45.61%[58]. - The net profit attributable to shareholders was CNY 116.48 million, an increase of 27.21% compared to the previous year[58]. - The company reported a net profit of 10,771.29 million yuan for the current period, representing a 38.39% increase compared to 7,783.32 million yuan in the same period last year[180]. Sales and Revenue Growth - The company's contrast agent products achieved sales revenue of CNY 404.57 million, representing a year-on-year growth of 38.43%[29]. - The sales revenue of the company's proprietary product, Jiuwei Zhenxin Granules, reached CNY 81.12 million, with a significant year-on-year increase of 103.34%[36]. - The revenue from the company's hypoglycemic products declined by 14.56%, totaling CNY 26.79 million due to significant price reductions after entering the national centralized procurement[36]. - The new iodine contrast agent raw material project at Haichang Pharmaceutical is expected to release at least 200 tons of iodine contrast agent capacity this year, contributing to a historical revenue high of CNY 66.62 million, a year-on-year increase of 2470.20%[37]. - The company’s gross margin for contrast agents was 66.39%, slightly down by 0.79% from the previous year[63]. - The company reported a significant increase in operating cash flow, amounting to CNY 102.58 million, a rise of 58.29%[61]. Investments and Projects - The company is actively advancing its fundraising projects, including the construction of a high-end intelligent injection workshop and a new solid preparation workshop in Cangzhou[40]. - The company has made significant progress in the construction of an 850-ton iodine contrast agent raw material project, with the iodine hexanol production line passing GMP compliance checks and officially commencing production[41]. - The company has ongoing research projects, including iodine propanol and iodine hexanol, with some products already receiving approval and others in the evaluation stage[49]. - The company is focusing on research and development of iodine contrast agents, with ongoing studies and preparations for domestic registration of products such as iodine hexanol and iodine propanol[41]. - The company has implemented different marketing strategies for its product lines, including academic promotion activities that reached nearly 3 million viewers nationwide[44]. Corporate Governance and Social Responsibility - The company is enhancing its corporate governance and investor relations, aiming for greater transparency and compliance with regulatory requirements[47]. - The company is committed to improving employee engagement and corporate culture through various initiatives and activities, fostering a vibrant and innovative work environment[48]. - The company donated 2 million RMB to support poverty alleviation efforts in a specific village, with a total of 1.4 million RMB donated from 2018 to the first half of 2021[113]. - The company donated 1.02 million boxes of its diabetes medication to help patients in underdeveloped regions, benefiting nearly 200,000 diabetes patients across more than 10 provinces[115]. Market Strategy and Expansion - The company has established good cooperation relationships with clients in multiple countries, including South Korea, Turkey, and India, while actively expanding its overseas market presence[41]. - The company is actively pursuing international registration for its contrast agent products, with submissions made in several non-standard market countries, expecting to increase the number of registered countries and regions by the end of the year[46]. - The company has a clear strategic focus on enhancing its market share in the contrast agent sector and expanding its overseas market presence, aiming to solidify its leading position in the industry[53]. - The company has implemented a flexible sales strategy to enhance brand influence and market share across its product lines[28]. Financial Position and Assets - The total assets at the end of the reporting period were approximately ¥2.91 billion, a 2.10% increase from ¥2.85 billion at the end of the previous year[21]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥1.83 billion, which is a 5.09% increase from ¥1.74 billion at the end of the previous year[21]. - The company has a total of ¥212,688,243.49 in restricted assets, including ¥24,452,576.40 in time deposit pledges and ¥147,730,193.82 in fixed asset mortgages[73]. - The total amount of raised funds was ¥48,922.45 million, with ¥15,355.45 million invested during the reporting period and a cumulative investment of ¥17,082.00 million[80]. - The company reported a long-term debt of approximately 175 million, down from 194 million, reflecting a decrease of about 10%[189]. Risks and Challenges - The company faces risks from industry policy changes, including increased regulatory scrutiny and centralized drug procurement, which has led to an average price drop of over 50% for some drugs[96][97]. - Haichang Pharmaceutical's iodinated contrast agent injection has been included in the fifth batch of national drug centralized procurement, while another product did not win a bid, creating uncertainty for future performance[97][98]. - The company plans to enhance quality management and reduce production costs to mitigate risks associated with procurement outcomes[98]. - Ongoing investments in R&D for new projects in contrast agents and other therapeutic areas are being made, despite the long approval timelines and market changes that may affect product launches[99].

Financial Performance - Revenue for Q1 2021 reached ¥222,075,960.67, an increase of 76.56% compared to ¥125,780,404.40 in the same period last year[8] - Net profit attributable to shareholders was ¥50,451,938.09, up 88.36% from ¥26,784,624.69 year-on-year[8] - Basic earnings per share increased by 91.11% to ¥0.1032 from ¥0.0540 in the previous year[8] - The company achieved operating revenue of 222.08 million yuan, a year-on-year increase of 76.56%[19] - The net profit attributable to shareholders reached 50.45 million yuan, up 88.36% year-on-year[22] - The company reported a total profit of ¥52,293,902.63 for Q1 2021, an increase of 68.0% from ¥31,098,889.25 in Q1 2020[59] - Net profit for Q1 2021 was ¥45,325,558.55, representing a 78.6% increase from ¥25,380,232.35 in Q1 2020[59] - Total operating revenue for Q1 2021 reached ¥222,075,960.67, a significant increase of 76.6% compared to ¥125,780,404.40 in the same period last year[57] - Earnings per share (EPS) for Q1 2021 were reported at ¥0.1032, compared to ¥0.0540 in the previous year[59] Cash Flow and Investments - The net cash flow from operating activities decreased by 13.51% to ¥47,200,999.98 compared to ¥54,574,319.53 in the same period last year[8] - Operating cash inflow from sales increased to ¥231,776,895.70, up from ¥188,819,097.51, representing a growth of approximately 22.8% year-over-year[65] - Total cash outflow from investment activities surged to ¥455,085,433.08, compared to ¥31,153,923.76 in the previous period, indicating a significant increase in investment spending[67] - Net cash flow from investment activities was negative at -¥424,149,576.66, worsening from -¥24,754,722.16 year-over-year[67] - Cash and cash equivalents at the end of the period stood at ¥615,431,981.12, down from ¥299,439,473.63, reflecting a decrease of approximately 51.3%[67] - Cash inflow from other investment activities reached ¥30,000,000.00, a substantial increase from ¥6,000,000.00 in the previous period[67] - Cash outflow for purchasing goods and services rose to ¥78,120,254.56, compared to ¥38,007,971.24, marking an increase of about 105.5%[65] - Cash paid to employees increased to ¥41,913,377.35 from ¥32,911,971.60, representing a rise of approximately 27.3%[65] - Cash flow from financing activities was negative at -¥3,438,433.51, compared to a positive inflow of ¥14,976,116.33 in the previous period[67] - The company experienced a net decrease in cash and cash equivalents of -¥380,359,746.45, contrasting with an increase of ¥44,831,634.87 in the prior period[67] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,869,515,216.74, a slight increase of 0.77% from ¥2,847,573,506.75 at the end of the previous year[8] - Total liabilities decreased from ¥955,500,130.72 to ¥931,351,066.02, a reduction of approximately 2.3%[47] - Total equity increased from ¥1,892,073,376.03 to ¥1,938,164,150.72, reflecting a growth of about 2.4%[49] - The company's total assets amounted to approximately CNY 2.87 billion, an increase from CNY 2.85 billion at the end of 2020[43] - The company's cash and cash equivalents decreased to CNY 631.14 million from CNY 1.01 billion at the end of 2020, reflecting a decline of approximately 37.8%[43] - The total current assets increased slightly to CNY 1.36 billion from CNY 1.35 billion, showing a growth of about 1%[43] - The company's accounts receivable rose to CNY 181.56 million, up from CNY 170.31 million, indicating an increase of approximately 6.9%[43] - Total assets increased from ¥2,300,416,515.10 to ¥2,356,163,536.39, a growth of about 2.4%[55] - The company's total equity attributable to shareholders rose from ¥1,741,905,282.13 to ¥1,793,106,642.12, an increase of approximately 2.9%[49] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 32,652[12] - The largest shareholder, Wang Daixue, holds 22.38% of the shares, totaling 110,683,213 shares[12] - The company’s major shareholder, Mr. Wang Daixue, reduced his holdings of convertible bonds on January 21, 2021[31] - The company’s major shareholder has pledged an additional 9,500,000 shares to Anxin Securities on April 23, 2021[31] Research and Development - Research and development expenses increased to ¥14,195,503.14, up 23.5% from ¥11,481,284.90 year-over-year[57] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[57] - The company has initiated the construction of a new contrast agent production line to ensure quality and supply[25] - The company plans to expand production capacity with the new 850-ton iodine contrast agent project, which has passed GMP compliance checks[24] - The company’s iodinated contrast agent injection has passed the consistency evaluation for generic drugs on April 20, 2021[31] - The company’s subsidiary, Zhejiang Haichang Pharmaceutical Co., Ltd., has completed GMP compliance inspections for its production lines[31] Financial Expenses - The company reported a significant increase in financial expenses, totaling 5.87 million yuan, up 427.44% year-on-year, mainly due to convertible bond provisions[20] - The company’s financial expenses rose to ¥5,873,411.93, compared to a negative expense of -¥1,793,745.99 in the previous year[57] - The investment income from associates and joint ventures was ¥266,871.23, a recovery from a loss of -¥660,786.13 in the same period last year[59]